Patents by Inventor Hugo Schmoekel

Hugo Schmoekel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8309518
    Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: November 13, 2012
    Assignees: Eidgenossische Technische Hochschule Zurich, Universitat Zurich
    Inventors: Jason C. Schense, Hugo Schmoekel, Jeffrey A. Hubbell, Franz Weber
  • Publication number: 20100291215
    Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
    Type: Application
    Filed: July 28, 2010
    Publication date: November 18, 2010
    Applicants: Eidgenossische Technische Hochschule, Universitat
    Inventors: Jason C. Schense, Hugo Schmoekel, Jeffrey Alan Hubbell, Franz Weber
  • Publication number: 20070202178
    Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
    Type: Application
    Filed: April 24, 2007
    Publication date: August 30, 2007
    Inventors: Jason Schense, Hugo Schmoekel, Jeffrey Hubbell, Franz Weber
  • Publication number: 20030012818
    Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF&bgr; superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
    Type: Application
    Filed: April 25, 2002
    Publication date: January 16, 2003
    Applicant: Eidgenossische Technische Hochschule Zurich and Universitat Zurich
    Inventors: Jason C. Schense, Hugo Schmoekel, Jeffrey Alan Hubbell, Franz Weber